161 related articles for article (PubMed ID: 20544351)
1. Allogeneic transplant outcomes are not affected by body mass index (BMI) in patients with haematological malignancies.
Nikolousis E; Nagra S; Paneesha S; Delgado J; Holder K; Bratby L; Chaganti S; Lovell R; Milligan D
Ann Hematol; 2010 Nov; 89(11):1141-5. PubMed ID: 20544351
[TBL] [Abstract][Full Text] [Related]
2. Allogeneic peripheral blood stem cell transplantation in patients with early-phase hematologic malignancy: a retrospective comparison of short-term outcome with bone marrow transplantation.
Lemoli RM; Bandini G; Leopardi G; Rosti G; Bonini A; Fortuna A; Rondelli D; Mangianti S; Motta MR; Rizzi S; Tassi C; Cavo M; Remiddi C; Curti A; Conte R; Tura S
Haematologica; 1998 Jan; 83(1):48-55. PubMed ID: 9542323
[TBL] [Abstract][Full Text] [Related]
3. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
4. A low body mass index is correlated with poor survival after allogeneic stem cell transplantation.
Le Blanc K; Ringdén O; Remberger M
Haematologica; 2003 Sep; 88(9):1044-52. PubMed ID: 12969813
[TBL] [Abstract][Full Text] [Related]
5. Prevention of graft-versus-host disease in high risk patients by depletion of CD4+ and reduction of CD8+ lymphocytes in the marrow graft.
Herrera C; Torres A; García-Castellano JM; Roman J; Martin C; Serrano J; Falcon M; Alvarez MA; Gomez P; Martinez F
Bone Marrow Transplant; 1999 Mar; 23(5):443-50. PubMed ID: 10100557
[TBL] [Abstract][Full Text] [Related]
6. Factors influencing the haematological recovery after allogeneic bone marrow transplantation in leukaemia patients treated with methotrexate-containing GVHD prophylaxis: a single-centre experience.
Hassan HT; Krog C; Stockschläder M; Schleimer B; Zeller W; Krüger W; Erttmann R; Zander AR
Anticancer Res; 1997; 17(1B):589-99. PubMed ID: 9066585
[TBL] [Abstract][Full Text] [Related]
7. Impact of postgrafting immunosuppressive regimens on nonrelapse mortality and survival after nonmyeloablative allogeneic hematopoietic stem cell transplant using the fludarabine and low-dose total-body irradiation 200-cGy.
Koh LP; Chen CS; Tai BC; Hwang WY; Tan LK; Ng HY; Linn YC; Koh MB; Goh YT; Tan B; Lim S; Lee YM; Tan KW; Liu TC; Ng HJ; Loh YS; Mow BM; Tan DC; Tan PH
Biol Blood Marrow Transplant; 2007 Jul; 13(7):790-805. PubMed ID: 17580257
[TBL] [Abstract][Full Text] [Related]
8. Fractionated total-body irradiation, etoposide, and cyclophosphamide followed by allogeneic bone marrow transplantation for patients with high-risk or advanced-stage hematological malignancies.
Long GD; Amylon MD; Stockerl-Goldstein KE; Negrin RS; Chao NJ; Hu WW; Nademanee AP; Snyder DS; Hoppe RT; Vora N; Wong R; Niland J; Reichardt VL; Forman SJ; Blume KG
Biol Blood Marrow Transplant; 1997 Dec; 3(6):324-30. PubMed ID: 9502300
[TBL] [Abstract][Full Text] [Related]
9. Unrelated umbilical cord blood transplantation for adults with haematological malignancies: results from a single Australian centre.
Bradstock KF; Hertzberg MS; Kerridge IH; Svennilson J; McGurgan M; Huang G; Antonenas V; Gottlieb DJ
Intern Med J; 2006 Jun; 36(6):355-61. PubMed ID: 16732860
[TBL] [Abstract][Full Text] [Related]
10. Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia.
Kröger N; Bornhäuser M; Ehninger G; Schwerdtfeger R; Biersack H; Sayer HG; Wandt H; Schäfer-Eckardt K; Beyer J; Kiehl M; Zander AR;
Ann Hematol; 2003 Jun; 82(6):336-42. PubMed ID: 12728337
[TBL] [Abstract][Full Text] [Related]
11. Impact of cyclosporine and methylprednisolone dose used for prophylaxis and therapy of graft-versus-host disease on survival and relapse after allogeneic bone marrow transplantation.
Michallet M; Perrin MC; Belhabri A; Molina L; Nicolini F; Tigaud JD; Sotto JJ; Guyotat D; Fière D; Archimbaud E
Bone Marrow Transplant; 1999 Jan; 23(2):145-50. PubMed ID: 10197799
[TBL] [Abstract][Full Text] [Related]
12. CD6+ T cell depleted allogeneic bone marrow transplantation from genotypically HLA nonidentical related donors.
Soiffer RJ; Mauch P; Fairclough D; Alyea E; Anderson K; Fisher D; Freedman A; Bartlett-Pandite L; Robertson M; Schlossman R; Gollob J; Marcus K; Murray C; Kuhlman C; Freeman A; Nadler L; Ritz J
Biol Blood Marrow Transplant; 1997 Apr; 3(1):11-7. PubMed ID: 9209736
[TBL] [Abstract][Full Text] [Related]
13. Successful allogeneic stem cell transplantation with nonmyeloablative conditioning in patients with relapsed hematologic malignancy following autologous stem cell transplantation.
Dey BR; McAfee S; Sackstein R; Colby C; Saidman S; Weymouth D; Poliquin C; Vanderklish J; Sachs DH; Sykes M; Spitzer TR
Biol Blood Marrow Transplant; 2001; 7(11):604-12. PubMed ID: 11760148
[TBL] [Abstract][Full Text] [Related]
14. Post-transplant outcome in chronic myeloid leukaemia.
Raza S; Ullah K; Ahmed P; Khan B; Kamal MK
J Coll Physicians Surg Pak; 2008 Oct; 18(10):615-9. PubMed ID: 18940118
[TBL] [Abstract][Full Text] [Related]
15. Low transplant-related mortality after second allogeneic peripheral blood stem cell transplant with reduced-intensity conditioning in adult patients who have failed a prior autologous transplant.
Martino R; Caballero MD; de la Serna J; Díez-Martín JL; Urbano-Ispízua A; Tomás JF; Odriozola J; León A; Canals C; San Miguel J; Sierra J
Bone Marrow Transplant; 2002 Jul; 30(2):63-8. PubMed ID: 12132043
[TBL] [Abstract][Full Text] [Related]
16. The predictive value of helper T lymphocyte precursor frequencies for graft-versus-host disease and graft-versus-leukaemia effects in allogeneic bone marrow transplantation.
Russell CA; Heilmann C; Madsen HO; Vindeløv LL
Bone Marrow Transplant; 2001 May; 27(9):949-58. PubMed ID: 11436105
[TBL] [Abstract][Full Text] [Related]
17. Effect of body mass index on mortality of patients with lymphoma undergoing autologous hematopoietic cell transplantation.
Navarro WH; Loberiza FR; Bajorunaite R; van Besien K; Vose JM; Lazarus HM; Rizzo JD
Biol Blood Marrow Transplant; 2006 May; 12(5):541-51. PubMed ID: 16635789
[TBL] [Abstract][Full Text] [Related]
18. Allogeneic stem cell transplantation reduces disease progression compared to autologous transplantation in patients with multiple myeloma.
Reynolds C; Ratanatharathorn V; Adams P; Braun T; Silver S; Ayash L; Carson E; Eisbruch A; Dawson LA; McDonagh K; Ferrara J; Uberti J
Bone Marrow Transplant; 2001 Apr; 27(8):801-7. PubMed ID: 11477436
[TBL] [Abstract][Full Text] [Related]
19. [Effects and prognostic factors of HLA-matched sibling donor allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia].
Tong XZ; Li J; Tan EX; Zhang GC; Wu XY; Peng AH; Zheng D; Zou WY; Hong WD; Luo SK
Zhonghua Zhong Liu Za Zhi; 2006 Jul; 28(7):545-8. PubMed ID: 17147125
[TBL] [Abstract][Full Text] [Related]
20. The relationship between body mass index and outcomes in leukemic patients undergoing allogeneic hematopoietic stem cell transplantation.
Hadjibabaie M; Tabeefar H; Alimoghaddam K; Iravani M; Eslami K; Honarmand H; Javadi MR; Khatami F; Ashouri A; Ghavamzadeh A
Clin Transplant; 2012; 26(1):149-55. PubMed ID: 21470311
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
